-
Innovation Ranking
NewInnovation Ranking – CK Hutchison Holdings Ltd
CK Hutchison Holdings Ltd (CK Hutchison) is a conglomerate that offers a range of services for various industries including retail, infrastructure, energy, finance and investment and telecommunications sectors. Its offerings include port development, ship and cargo services, energy infrastructure services, mobile and broadband-related services, and manufacturing and distribution of healthcare, personal care, medicines, related products to the consumers. CK Hutchison also earns returns from investments in companies such as Hutchison Whampoa (China), Hutchison China MediTech, CK Life Sciences, TOM Group,...
-
Innovation Ranking
NewInnovation Ranking – Hutchison China MediTech Ltd
Hutchmed China Ltd (Hutchmed) formerly known as Hutchison China MediTech Ltd is a biopharmaceutical company that discovers, develops, manufactures, and commercializes drugs for the treatment of solid tumors and hematological malignancies, and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in...
-
Company Insights
Innovation and Patenting activity of Hutchison Port Holdings Trust Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Hutchison Port Holdings Trust Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
Innovation and Patenting activity of CK Hutchison Holdings Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CK Hutchison Holdings Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
Innovation and Patenting activity of Hutchison Telecommunications Hong Kong Holdings Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Hutchison Telecommunications Hong Kong Holdings Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Sector Analysis
NewESG State of Play and Telco Approaches
ESG State of Play and Telco Approaches Report Overview Major tech and telecom companies have a stated commitment to ESG, but their goals, delivery, and reporting can vary substantially. TMT companies are among the key players in the race to net zero. They are not only reducing their carbon footprint, but also enabling others to decarbonize by offering solutions for resource optimization, productivity enhancement, and innovation support. Many telecom operators are publishing sustainability reports which have substantial detail on areas...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-441566 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAR-441566 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAR-441566 in Rheumatoid Arthritis Drug Details: SAR-441566 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNG-462 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNG-462 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNG-462 in Solid Tumor Drug Details: TNG-462 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Sicca Syndrome (Sjogren) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Sicca Syndrome (Sjogren) Drug Details: Acloproxalap (ADX-629) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Mantle Cell Lymphoma Drug Details: Sovleplenib (HMPL-523) is under...